Skip to main content

Table 2 Survival data and univariate analyses

From: Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer

 

med PFS

HR (95% CI)

med OS

HR (95% CI)

SE-Region

5.2 (3.4–7.0)

10.9 (7.8–14.0)

MPACT (Gem/Nab-arm)

5.5 (4.5–5.9)

8.5 (7.9–9.5)

Subgroup analysis

 Tumour stage

  Locally adv.

6.8 (5.2–8.4)

0.82 (0.48–1.40) p = 0.47

17.1 (7.6–26.6)

0.62 (0.32–1.18) p = 0.14

  Metastasised

4.5 (3.3–5.7)

9.4 (4.9–13.9)

 Metastatic burden

  1–3 metastases

5.5 (2.5–8.5)

0.99 (0.53–1.86) p = 0.97

10.9 (5.5–16.3)

0.63 (0.30–1.32) p = 0.22

   > 3 metastases

3.9 (2.4–5.4)

6.9 (4.8–9.0)

 ECOG

  0

6.2 (3.9–8.5)

0.93 (0.56–1.54) p = 0.77

14.5 (7.5–21.5)

0.73 (0.40–1.31) p = 0.29

  1–2

4.5 (1.1–7.9)

9.4 (6.3–12.5)

Prior chemotherapy

  Yes

6.5 (2.9–10.1)

0.82 (0.48–1.38) p = 0.45

13.2 (9.4–17.0)

0.81 (0.44–1.46) p = 0.48

  No

5.1 (3.0–7.2)

8.2 (5.3–11.1)

 Prior Surgery

  Yes

5.5 (2.1–8.9)

0.89 (0.53–1.50) p = 0.67

12.0 (9.0–15.0)

0.87 (0.48–1.58) p = 0.64

  No

5.1 (2.8–7.4)

8.9 (5.3–12.5)

  1. Survival data in months (95% CI). Upper part shows data for the entire cohort compared to the MAPCT-trial. Lower part displays univariate analyses in the respective subgroups. HR hazard ratio calculated using Cox regression analysis